Tumors Clinical Trials

870 recruitingLast updated: May 29, 2026

There are 870 actively recruiting tumors clinical trials across 59 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Tumors Trials at a Glance

870 actively recruiting trials for tumors are listed on ClinicalTrialsFinder across 6 cities in 59 countries. The largest study group is Phase 1 with 517 trials, with the heaviest enrollment activity in Houston, Beijing, and New York. Lead sponsors running tumors studies include National Cancer Institute (NCI), Suzhou Suncadia Biopharmaceuticals Co., Ltd., and M.D. Anderson Cancer Center.

Treatments under study

About Tumors Clinical Trials

Looking for clinical trials for Tumors? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 870 trials

Recruiting
Phase 1Phase 2

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Advanced Solid Tumors
ModernaTX, Inc.361 enrolled31 locationsNCT05533697
Recruiting
Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Neuroendocrine CarcinomaCarcinoma, NeuroendocrineTumor, Neuroendocrine+2 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06406465
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 1Phase 2

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Brain CancerGBMGlioma+12 more
National Institute of Neurological Disorders and Stroke (NINDS)40 enrolled1 locationNCT07416188
Recruiting
Phase 1

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

Solid TumorsSarcomas
Zai Lab (Shanghai) Co., Ltd.180 enrolled5 locationsNCT07374848
Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled12 locationsNCT07335497
Recruiting
Phase 1Phase 2

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Metastatic Solid TumorsLocally Advanced Solid Tumors
Turning Point Therapeutics, Inc.500 enrolled165 locationsNCT03093116
Recruiting
Phase 1

A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors

Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.22 enrolled1 locationNCT07591155
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled8 locationsNCT07288359
Recruiting
Phase 1

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Advanced Solid Tumors
Gilead Sciences278 enrolled7 locationsNCT06167317
Recruiting
Phase 1Phase 2

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.111 enrolled1 locationNCT07469774
Recruiting
Phase 1

A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech41 enrolled5 locationsNCT07541534
Recruiting
Phase 1Phase 2

A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.120 enrolled2 locationsNCT06922357
Recruiting
Phase 1

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.189 enrolled14 locationsNCT06248411
Recruiting
Phase 1Phase 2

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

Solid Tumors, Adult
Hutchmed147 enrolled16 locationsNCT07228247
Recruiting
Phase 1

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

Solid TumorsImmunotherapyCold Exposure+1 more
West China Hospital24 enrolled1 locationNCT07538479
Recruiting
Phase 1

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
Changchun GeneScience Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07407504
Recruiting
Phase 1

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors
University of California, San Diego18 enrolled1 locationNCT07171203
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222